<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>162</id><JournalTitle>ANTI-TUBERCULAR DRUGS: MECHANISMS OF ACTION AND MULTIDRUG RESISTANCE</JournalTitle><Abstract>Tuberculosis (TB) is a serious worldwide health risk, with the increase in the Multidrug-resistant (MDR-TB) and highly
resistant to drugs (XDR-TB) TB. Although the world is experiencing technological advancements on diagnosis, treatment
regimens and understanding of TB pathogenesis, the disease remains a menace to global health systems, especially in the lower
and middle-income nations where other socio-economic issues like poverty, malnutrition, and HIV co-infection further
contribute to its management complications. Drug-sensitive TB is traditionally treated with pharmacotherapy (combination of
first-line drugs, including isoniazid, rifampicin, pyrazinamide, and ethambutol). Nevertheless, the rise of MDR-TB and XDRTB brings about the need to prescribe second-line drugs that are more toxic and have prolonged treatment regimes. Newer
medications such as bedaquiline, pretomanid, and delamanid have become a promising therapy in the treatment of resistant
strains, yet the development of resistance to these medications is another problem. Coupled with pharmacotherapy, new
technologies like vaccines, immunotherapy, and computers and mobile apps like artificial intelligence (AI) and mobile health
apps promise an opportunity to enhance early detection, treatment adherence, and compliance. A combination of novel
technologies, research, and enhanced patient-centered care plans will be the future in TB control in order to surmount the
challenges of drug resistance to achieve global eradication of TB. The final target is to eliminate TB by 2035, which is to be
reached through joint efforts of the international community and improved access to quality diagnostics, treatment as well as
preventive measures.</Abstract><Email>-</Email><articletype>Research</articletype><volume>16</volume><issue>1</issue><year>2026</year><keyword>Tuberculosis (TB), Multidrug-Resistant TB (MDR-TB), Extensively Drug-Resistant TB (XDR-TB), Pharmacotherapy, Drug Resistance</keyword><AUTHORS>Naga Greeshma M, Divya Sri N, Lahari B, Sai Neha Sri N,Dr Lavanya A</AUTHORS><afflication>Pharm. D, V Year Student, Department of Pharmacy Practice, KLR Pharmacy College, Paloncha, Telangana, India.,Assistant Professor, Department of Pharmacy Practice, KLR Pharmacy College, Paloncha, Telangana, India</afflication></Article></Articles>